Department of Internal Medicine and Medical Disciplines, Sapienza Rome University, 00161 Rome, Italy.
J Clin Endocrinol Metab. 2013 Jul;98(7):2709-15. doi: 10.1210/jc.2013-1586. Epub 2013 Jun 13.
We previously showed that a single high dose of oral (po) cholecalciferol (D₃) sharply increases serum 25-hydroxyvitamin D [25(OH)D].
We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D₂) or D₃.
This was a prospective intervention study.
The study was conducted in an ambulatory care setting.
Participants were 24 subjects with hypovitaminosis D.
A single dose of 600,000 IU of po or im D₂ or D₃ was administered.
Serum 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)₂D] were measured at baseline and at days 30, 60, 90, and 120 by RIA. Serum 1,25(OH)₂D₂, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], 24,25-hydroxyvitamin D₂ [24,25(OH)D₂], and 24,25-hydroxyvitamin D₃ [24,25(OH)D₃] were measured by liquid chromatography-tandem mass spectrometry in a subgroup of patients receiving the po formulations.
The areas under the curve of 25(OH)D after D₃ were significantly higher than those after D₂ (P < .0001). Serum 25(OH)D basal difference significantly increased at day 30 with po D₂ and D₃ (P < .01 and P < .0001) and up to day 90 with po D₃ (P < .01). The im formulations produced a slow increased, and values peaked at day 120 relative to the other time points (P < .0001). We found a decrease in 1,25(OH)₂D at day 30 (P < .05) and up to day 120 (P < .001) and an increase in 1,25(OH)₂D₂ at day 30 (P < .01) and up to day 120 (P < .01) after po D₂. Oral D₂ and D₃ produced increases in 24,25(OH)D₂ and 24,25(OH)D₃, respectively, at day 30 (P < .001).
A po dose of 600,000 IU of D₂ or D₃ is initially more effective in increasing serum 25(OH)D than the equivalent im dose and is rapidly metabolized. Our RIA assay for 1,25(OH)₂D may not recognize 1,25(OH)₂D₂.
我们之前的研究表明,单次口服(po)大剂量胆钙化醇(D₃)可显著提高血清 25-羟维生素 D [25(OH)D]水平。
我们评估了单次 po 或肌内(im)给予大剂量麦角钙化醇(D₂)或 D₃ 的长期生物利用度和代谢情况。
这是一项前瞻性干预研究。
研究在门诊环境中进行。
24 例维生素 D 缺乏症患者。
给予 600,000IU 的 po 或 im D₂ 或 D₃。
基线时和第 30、60、90 和 120 天时,采用放射免疫分析法(RIA)检测血清 25(OH)D 和 1,25-二羟维生素 D [1,25(OH)₂D]。在接受 po 制剂的患者亚组中,采用液相色谱-串联质谱法(LC-MS/MS)检测血清 1,25-二羟维生素 D₂ [1,25(OH)₂D₂]、1,25-二羟维生素 D₃ [1,25(OH)₂D₃]、24,25-二羟维生素 D₂ [24,25(OH)D₂]和 24,25-二羟维生素 D₃ [24,25(OH)D₃]。
D₃ 后的 25(OH)D 曲线下面积明显高于 D₂(P<0.0001)。po D₂ 和 D₃ 在第 30 天(P<0.01 和 P<0.0001)和第 90 天(P<0.01)时血清 25(OH)D 基础差异显著增加。im 制剂产生缓慢增加,与其他时间点相比,第 120 天达到峰值(P<0.0001)。我们发现第 30 天(P<0.05)和第 120 天(P<0.001)时 1,25(OH)₂D 下降,第 30 天(P<0.01)和第 120 天(P<0.01)时 1,25(OH)₂D₂增加。po D₂ 和 D₃ 分别在第 30 天(P<0.001)增加了 24,25-二羟维生素 D₂和 24,25-二羟维生素 D₃。
po 给予 600,000IU 的 D₂ 或 D₃ 比等量 im 剂量更能有效提高血清 25(OH)D 水平,且代谢迅速。我们用于检测 1,25(OH)₂D 的 RIA 检测可能无法识别 1,25(OH)₂D₂。